[1] 中国抗癌协会肝癌专业委员会,中国抗癌协会临床肿瘤学协作专业委员会,中华医学会肝病学分会肝癌学组. 原发性肝癌规范化诊治专家共识.肿瘤,2009,29(4): 295-304. [2] 中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版). 临床肿瘤学杂志,2011,16(10):929-946. [3] Wu FS,Zhao WH,Liang TB,et al.Survival factors after resection of small hepatocellular carcinoma.Hepatobiliary Pancreat Disint,2005,4(3):379-384. [4] 张辉,徐新保,何晓军,等.原发性肝癌术后肝内复发:再手术还是射频消融.医学与哲学,2013,34 (8B):25-26. [5] 方万强,李升平,张昌卿,等.小肝癌切缘复发预防及临床处理方法的探讨.癌症,2005,24(7):834-836. [6] 何磊,刘斌. 小肝癌的治疗进展. 中国肿瘤外科杂志,2013,5(5):319-321. [7] 张松,王磊,吴晓东,等. 伽马刀联合HIFU治疗小肝癌的临床观察. 医疗论坛杂志,2014,35(9):28-30. [8] 李俊.小肝癌的诊断与治疗体会.中国医学工程,2014,22(10):38-39. [9] 杨秉辉,丛文铭,周晓军,等. 原发性肝癌规范化诊治专家共识.实用肝脏病杂志,2009,12(5):321-328. [10] Miyayama S,Yamashiro M,Omuda M,et al.The march of extrahepatic collaterals:Analysis of blood supply to hepatocellularcarcinoma located in the bare area of the liver after chemoembolization. Cardiovasc Intervent Radiol,2010,33(3):513-522. [11] Xiao EH,Guo D,Bian DJ,et al. Effect of preoperative transcatheter arterial chemoembolization on angiogenesis of hepatocellular carcinoma cells.World J Gastroenterol,2009,15(36):4582-4586. [12] Kubo S,Taukamoto T,Hirohashi K,et al. Appropriate surgical management of small hepatocellular carcinomas in patients infected with hepatitis C virus. World J Surg,2003,27(4): 437-442. [13] 易城辉,丁来贵,袁福建,等.TACE术在肝癌治疗中的作用及其疗效分析.中国实用医药,2009,4(1):96-97. [14] 汪盛参,曾庆乐,陈勇,等.微导管超选择插管介入治疗小肝癌的疗效.实用医学杂志,2012, 28(11):1850-1852. [15] 陈晓明,罗鹏飞,邵培坚,等.肝癌阶段性栓塞化疗与常规栓塞化疗的比较研究.中华放射学杂志,2000,34(4):271-273. [16] Tsochatzis EA,Bosch J,Burroughs AK,et al. Liver cirrhosis. Lancet,2014,383(9930):1749-1761. [17] Minami Y,Minami T,Chishina H,et al. Balloon-occluded transcatheter arterial chemoem-bolization for hepatocellular carcinoma:A single-center experience. Oncology,2015,89(2):27-32. [18] Li Q,Ao GK,Duan F,et al. Incidence and therapeutic frequency of extrahepatic collateral arteries intranscatheter arterial chemoembolization of hepatocellular carcinoma: Experience from 182 patients with survival time more than 3 years. Eur J Radiol,2015,84(12):2555-2563. [19] Ohki T,Sato K,Yamagami M,et al. Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan:A retrospective analysis. Clin Drug Investig,2015,35(11):751-759. [20] Divella R,Daniele A,Abbate I,et al. Circulating levels of PAI-1 and SERPINE1 4G/4G polymorphism are predictive of poor prognosis in HCC patients undergoing TACE. Transl Oncol,2015,8(4):273-278. [21] Wu H,Liu S,Zheng J,et al. Transcatheter arterial chemoembolization(TACE) for lymph node metastases in patients with hepatocellular carcinoma. J Surg Oncol,2015,112(4):372-376. [22] Liao J,Xiao J,Zhou Y,et al. Effect of transcatheter arterial chemoembolization on cellular immune function and regulatory T cells in patients with hepatocellular carcinoma. Mol Med Rep,2015,12(4):6065-6071. [23] Huo YR,Eslick GD. Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma:A systematic review and Meta-analysis. JAMA Oncol,2015,1(6):756-765. [24] Yao X,Yan D,Liu D,et al. Efficacy and adverse events of transcatheter arterial chemoembolization in combination with sorafenib in the treatment of unresectable hepatocellular carcinoma. Mol Clin Oncol,2015,3(4):929-935. [25] Shiozawa K,Watanabe M,Ikehara T,et al. Efficacy of sorafenib versus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. Gan To Kagaku Ryoho,2015,42(8):953-956. |